市場調查報告書
商品編碼
1029200

全球偏頭痛藥物市場:行業趨勢、市場份額、市場規模、增長、機會、預測(2021-2026)

Migraine Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

出版日期: | 出版商: IMARC Services Private Limited | 英文 146 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

2015 年至 2020 年,全球偏頭痛藥物市場規模呈現強勁增長。展望未來,預計該市場將在 2021 年至 2026 年間以約 12% 的複合年增長率增長。

偏頭痛的流行和診斷數量的顯著增加是推動市場增長的關鍵因素之一。偏頭痛治療報銷系統的改進和對精準藥物日益增長的需求也促進了市場的增長。

此外,在後期管道中的一類具有較高臨床效果的新藥,例如對用於治療偏頭痛的電神經素刺激劑的需求增加以及降鈣素基因相關□(CGRP)單克隆抗體的引入。預期批准是也是市場增長的動力。

本報告調查了全球偏頭痛藥物市場,並提供了全面的信息,包括市場概況、市場分析、價格分析、競爭格局和公司概況。

目錄

第一章前言

第二章範圍和調查方法

第 3 章執行摘要

第 4 章介紹

第 5 章全球偏頭痛藥物市場

  • 市場概覽
  • 市場表現
  • COVID-19 的影響

第 6 章市場細分:按治療類型

  • 進程抑制處理
  • 預防性治療

第 7 章市場細分:按藥物類型

  • 曲坦
  • 小麥角生物鹼
  • 非甾體抗炎藥
  • 乙□膽鹼抑製劑/神經毒素
  • 大談
  • CGRP 單克隆抗體
  • 其他

第 8 章市場細分:按管理途徑

  • 口服
  • 注入
  • 其他

第 9 章市場細分:按分銷渠道

  • 醫院藥房
  • 零售藥店
  • 其他

第 10 章市場細分:按地區

  • 北美
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳大利亞
    • 印度尼西亞
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 意大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場細分:按國家/地區

第11章SWOT分析

第十二章價值鏈分析

第十三章波特五力分析

第14章價格分析

第15章競爭形勢

  • 市場結構
  • 主要公司
  • 主要公司簡介
    • Abbott Laboratories
    • Allergan Plc(Abbvie Inc.)
    • Amgen Inc.
    • AstraZeneca Plc
    • Bausch Health Companies Inc.(舊社名 Valeant Pharmaceuticals)
    • Eisai Co. Ltd.
    • Eli Lilly and Company
    • Endo International Plc
    • GlaxoSmithKline Plc
    • Johnson & Johnson
    • Merck & Co.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Teva Pharmaceutical Industries Limited
目錄
Product Code: SR1020F150_Report

The global migraine drugs market exhibited strong growth during 2015-2020. Migraine is a neurological condition that causes unilateral or throbbing pain in the forehead, side of the head or around the eyes. The pain is often accompanied by autonomic symptoms, such as nausea, vomiting, photophobia and phonophobia. Migraine is generally diagnosed by examining the patient's medical history and symptoms, as well as by performing blood tests, and magnetic resonance imaging (MRI) and computerized tomography (CT) scans. At present, over the counter (OTC) medicines and prescribed injections are available to relieve the symptoms and reduce the frequency and severity of migraine attacks. These drugs are either taken regularly or during attacks or exacerbations of chronic pain.

A significant rise in the prevalence and diagnosis of migraine represents one of the key factors bolstering the market growth. Apart from this, the improvement in reimbursement policies for migraine medications, along with the escalating demand for precision medicines, is also contributing to the market growth. Furthermore, the growing demand for electrical nerve stimulating devices to treat migraine and the expected approval of new classes of drugs that are in late-stage pipeline and have higher clinical efficacy, such as the introduction of calcitonin gene-related peptide (CGRP) monoclonal antibodies, are also driving the market growth. Besides this, the testing of migraine drugs for the treatment of the coronavirus disease (COVID-19) is expected to create a positive influence on the market growth. For instance, Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, which was examining Zavegepant for the treatment of acute migraines, has commenced the clinical trial on the same drug to mitigate the neuro-immune consequences among COVID-19 patients. However, a decline in clinical visits and procedural treatment of migraines due to social distancing norms has impacted the market growth. Looking forward, IMARC Group expects the global migraine drugs market to grow at a CAGR of around 12% during 2021-2026.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each sub-segment of the global migraine drugs market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, treatment type, drug type, route of administration and distribution channel.

Breakup by Treatment Type:

  • Abortive Treatment
  • Preventive Treatment

Breakup by Drug Type:

  • Triptans
  • Ergot Alkaloids
  • NSAIDs
  • Acetylcholine Inhibitors/ Neurotoxins
  • Ditans
  • CGRP mAbs
  • Others

Breakup by Route of Administration:

  • Oral
  • Injectable
  • Others

Breakup by Distribution Channel:

  • Hospital-Based Pharmacies
  • Retail Pharmacies
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Allergan Plc (Abbvie Inc.), Amgen Inc., AstraZeneca Plc, Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals), Eisai Co. Ltd., Eli Lilly and Company, Endo International Plc, GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Novartis AG, Pfizer Inc., Sanofi SA and Teva Pharmaceutical Industries Limited. Key Questions Answered in This Report:

  • How has the global migraine drugs market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global migraine drugs market?
  • What are the key regional markets?
  • What is the breakup of the market based on the treatment type?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global migraine drugs market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Migraine Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Abortive Treatment
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Preventive Treatment
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 Triptans
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Ergot Alkaloids
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 NSAIDs
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Acetylcholine Inhibitors/ Neurotoxins
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Ditans
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 CGRP mAbs
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Others
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Oral
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Injectable
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital-Based Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Allergan Plc (Abbvie Inc.)
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 SWOT Analysis
    • 15.3.3 Amgen Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 SWOT Analysis
    • 15.3.4 AstraZeneca Plc
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals)
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Eisai Co. Ltd.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Eli Lilly and Company
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Endo International Plc
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 GlaxoSmithKline Plc
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Johnson & Johnson
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Merck & Co.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Novartis AG
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13 Pfizer Inc.
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials
      • 15.3.13.4 SWOT Analysis
    • 15.3.14 Sanofi SA
      • 15.3.14.1 Company Overview
      • 15.3.14.2 Product Portfolio
      • 15.3.14.3 Financials
      • 15.3.14.4 SWOT Analysis
    • 15.3.15 Teva Pharmaceutical Industries Limited
      • 15.3.15.1 Company Overview
      • 15.3.15.2 Product Portfolio
      • 15.3.15.3 Financials
      • 15.3.15.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Migraine Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Migraine Drugs Market: Sales Value (in Billion US$), 2015-2020
  • Figure 3: Global: Migraine Drugs Market: Breakup by Treatment Type (in %), 2020
  • Figure 4: Global: Migraine Drugs Market: Breakup by Drug Type (in %), 2020
  • Figure 5: Global: Migraine Drugs Market: Breakup by Route of Administration (in %), 2020
  • Figure 6: Global: Migraine Drugs Market: Breakup by Distribution Channel (in %), 2020
  • Figure 7: Global: Migraine Drugs Market: Breakup by Region (in %), 2020
  • Figure 8: Global: Migraine Drugs Market Forecast: Sales Value (in Billion US$), 2021-2026
  • Figure 9: Global: Migraine Drugs (Abortive Treatment) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 10: Global: Migraine Drugs (Abortive Treatment) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 11: Global: Migraine Drugs (Preventive Treatment) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 12: Global: Migraine Drugs (Preventive Treatment) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 13: Global: Migraine Drugs (Triptans) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 14: Global: Migraine Drugs (Triptans) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 15: Global: Migraine Drugs (Ergot Alkaloids) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 16: Global: Migraine Drugs (Ergot Alkaloids) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 17: Global: Migraine Drugs (NSAIDs) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 18: Global: Migraine Drugs (NSAIDs) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 19: Global: Migraine Drugs (Acetylcholine Inhibitors/ Neurotoxins) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 20: Global: Migraine Drugs (Acetylcholine Inhibitors/ Neurotoxins) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 21: Global: Migraine Drugs (Ditans) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 22: Global: Migraine Drugs (Ditans) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 23: Global: Migraine Drugs (CGRP mAbs) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 24: Global: Migraine Drugs (CGRP mAbs) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 25: Global: Migraine Drugs (Other Drug Types) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 26: Global: Migraine Drugs (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 27: Global: Migraine Drugs (Oral) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 28: Global: Migraine Drugs (Oral) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 29: Global: Migraine Drugs (Injectable) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 30: Global: Migraine Drugs (Injectable) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 31: Global: Migraine Drugs (Other Routes of Administration) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 32: Global: Migraine Drugs (Other Routes of Administration) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 33: Global: Migraine Drugs (Hospital-Based Pharmacies) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 34: Global: Migraine Drugs (Hospital-Based Pharmacies) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 35: Global: Migraine Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 36: Global: Migraine Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 37: Global: Migraine Drugs (Other Distribution Channels) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 38: Global: Migraine Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 39: North America: Migraine Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 40: North America: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 41: United States: Migraine Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 42: United States: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 43: Canada: Migraine Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 44: Canada: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 45: Asia Pacific: Migraine Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 46: Asia Pacific: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 47: China: Migraine Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 48: China: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 49: Japan: Migraine Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 50: Japan: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 51: India: Migraine Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 52: India: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 53: South Korea: Migraine Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 54: South Korea: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 55: Australia: Migraine Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 56: Australia: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 57: Indonesia: Migraine Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 58: Indonesia: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 59: Others: Migraine Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 60: Others: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 61: Europe: Migraine Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 62: Europe: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 63: Germany: Migraine Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 64: Germany: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 65: France: Migraine Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 66: France: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 67: United Kingdom: Migraine Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 68: United Kingdom: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 69: Italy: Migraine Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 70: Italy: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 71: Spain: Migraine Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 72: Spain: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 73: Russia: Migraine Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 74: Russia: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 75: Others: Migraine Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 76: Others: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 77: Latin America: Migraine Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 78: Latin America: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 79: Brazil: Migraine Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 80: Brazil: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 81: Mexico: Migraine Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 82: Mexico: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 83: Others: Migraine Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 84: Others: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 85: Middle East and Africa: Migraine Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 86: Middle East and Africa: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 87: Global: Migraine Drugs Industry: SWOT Analysis
  • Figure 88: Global: Migraine Drugs Industry: Value Chain Analysis
  • Figure 89: Global: Migraine Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Migraine Drugs Market: Key Industry Highlights, 2020 and 2026
  • Table 2: Global: Migraine Drugs Market Forecast: Breakup by Treatment Type (in Million US$), 2021-2026
  • Table 3: Global: Migraine Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2021-2026
  • Table 4: Global: Migraine Drugs Market Forecast: Breakup by Route of Administration (in Million US$), 2021-2026
  • Table 5: Global: Migraine Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2021-2026
  • Table 6: Global: Migraine Drugs Market Forecast: Breakup by Region (in Million US$), 2021-2026
  • Table 7: Global: Migraine Drugs Market Structure
  • Table 8: Global: Migraine Drugs Market: Key Players